ProtoKinetix, Incorporated (PKTX)
USD 0.01
(-16.79%)
USD 0.01
(-16.79%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 | -415.47 Thousand USD | 78.22% |
| 2022 | -1.9 Million USD | 18.12% |
| 2021 | -2.32 Million USD | 69.53% |
| 2020 | -7.64 Million USD | -82.1% |
| 2019 | -4.19 Million USD | -245.12% |
| 2018 | -1.21 Million USD | 19.64% |
| 2017 | -1.51 Million USD | 0.72% |
| 2016 | -1.52 Million USD | -21.51% |
| 2015 | -1.25 Million USD | -644.78% |
| 2014 | -168.47 Thousand USD | 62.44% |
| 2013 | -448.57 Thousand USD | -127.57% |
| 2012 | -197.11 Thousand USD | 84.0% |
| 2011 | -1.23 Million USD | 11.29% |
| 2010 | -1.38 Million USD | -9.34% |
| 2009 | -1.27 Million USD | 18.1% |
| 2008 | -1.55 Million USD | 43.16% |
| 2007 | -2.72 Million USD | -38.66% |
| 2006 | -1.96 Million USD | 61.39% |
| 2005 | -5.09 Million USD | 5.42% |
| 2004 | -5.38 Million USD | -252.41% |
| 2003 | -1.52 Million USD | -10176.89% |
| 2002 | -14.87 Thousand USD | 11.97% |
| 2001 | -16.9 Thousand USD | -48191.43% |
| 2000 | -35.00 USD | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q2 | -85.07 Thousand USD | 7.55% |
| 2024 Q1 | -92.02 Thousand USD | 18.18% |
| 2023 Q2 | -115.57 Thousand USD | -7.98% |
| 2023 Q1 | -107.03 Thousand USD | 81.66% |
| 2023 FY | -415.47 Thousand USD | 78.22% |
| 2023 Q3 | -80.39 Thousand USD | 30.44% |
| 2023 Q4 | -112.47 Thousand USD | -39.91% |
| 2022 Q1 | -517.59 Thousand USD | -31.32% |
| 2022 Q2 | -442.15 Thousand USD | 14.57% |
| 2022 FY | -1.9 Million USD | 18.12% |
| 2022 Q4 | -583.65 Thousand USD | -57.73% |
| 2022 Q3 | -370.04 Thousand USD | 16.31% |
| 2021 FY | -2.32 Million USD | 69.53% |
| 2021 Q1 | -133.07 Thousand USD | 77.13% |
| 2021 Q2 | -403.73 Thousand USD | -203.39% |
| 2021 Q3 | -1.4 Million USD | -247.26% |
| 2021 Q4 | -394.15 Thousand USD | 71.89% |
| 2020 Q4 | -581.81 Thousand USD | 65.52% |
| 2020 Q3 | -1.68 Million USD | 23.5% |
| 2020 Q2 | -2.2 Million USD | 30.4% |
| 2020 Q1 | -3.16 Million USD | -29.13% |
| 2020 FY | -7.64 Million USD | -82.1% |
| 2019 Q2 | -769.24 Thousand USD | -101.14% |
| 2019 FY | -4.19 Million USD | -245.12% |
| 2019 Q1 | -382.45 Thousand USD | -97.48% |
| 2019 Q3 | -591.92 Thousand USD | 23.05% |
| 2019 Q4 | -2.45 Million USD | -314.62% |
| 2018 Q2 | -344.33 Thousand USD | -12.32% |
| 2018 Q1 | -306.57 Thousand USD | 39.6% |
| 2018 Q3 | -371.77 Thousand USD | -7.97% |
| 2018 Q4 | -193.66 Thousand USD | 47.91% |
| 2018 FY | -1.21 Million USD | 19.64% |
| 2017 Q3 | -299.29 Thousand USD | 9.69% |
| 2017 FY | -1.51 Million USD | 0.72% |
| 2017 Q1 | -375.36 Thousand USD | -0.16% |
| 2017 Q2 | -331.39 Thousand USD | 11.71% |
| 2017 Q4 | -507.58 Thousand USD | -69.59% |
| 2016 Q1 | -344.85 Thousand USD | 27.41% |
| 2016 Q2 | -372.95 Thousand USD | -8.15% |
| 2016 Q3 | -432.07 Thousand USD | -15.85% |
| 2016 Q4 | -374.75 Thousand USD | 13.27% |
| 2016 FY | -1.52 Million USD | -21.51% |
| 2015 Q1 | -265.12 Thousand USD | -151599.43% |
| 2015 Q4 | -475.08 Thousand USD | -108.82% |
| 2015 Q3 | -227.5 Thousand USD | 20.75% |
| 2015 Q2 | -287.08 Thousand USD | -8.28% |
| 2015 FY | -1.25 Million USD | -644.78% |
| 2014 Q4 | 175.00 USD | 101.25% |
| 2014 Q3 | -13.96 Thousand USD | 79.87% |
| 2014 Q2 | -69.34 Thousand USD | 18.75% |
| 2014 Q1 | -85.34 Thousand USD | 48.96% |
| 2014 FY | -168.47 Thousand USD | 62.44% |
| 2013 FY | -448.57 Thousand USD | -127.57% |
| 2013 Q2 | -94.68 Thousand USD | -6.61% |
| 2013 Q4 | -167.21 Thousand USD | -70.87% |
| 2013 Q3 | -97.86 Thousand USD | -3.36% |
| 2013 Q1 | -88.81 Thousand USD | -82.93% |
| 2012 Q2 | -39.48 Thousand USD | 40.5% |
| 2012 Q3 | -44.22 Thousand USD | -12.01% |
| 2012 Q4 | -48.55 Thousand USD | -9.78% |
| 2012 FY | -197.11 Thousand USD | 84.0% |
| 2012 Q1 | -66.35 Thousand USD | 86.93% |
| 2011 Q2 | -186.65 Thousand USD | 58.15% |
| 2011 Q1 | -446 Thousand USD | -15.16% |
| 2011 Q3 | -91.4 Thousand USD | 51.03% |
| 2011 FY | -1.23 Million USD | 11.29% |
| 2011 Q4 | -507.87 Thousand USD | -455.63% |
| 2010 Q1 | -173.12 Thousand USD | 74.7% |
| 2010 Q3 | -588.78 Thousand USD | -182.61% |
| 2010 Q4 | -387.29 Thousand USD | 34.22% |
| 2010 FY | -1.38 Million USD | -9.34% |
| 2010 Q2 | -208.33 Thousand USD | -20.34% |
| 2009 Q1 | -128.88 Thousand USD | 22.92% |
| 2009 Q4 | -684.21 Thousand USD | -144.37% |
| 2009 Q3 | -279.98 Thousand USD | -58.17% |
| 2009 FY | -1.27 Million USD | 18.1% |
| 2009 Q2 | -177.02 Thousand USD | -37.35% |
| 2008 FY | -1.55 Million USD | 43.16% |
| 2008 Q3 | -429.51 Thousand USD | 30.2% |
| 2008 Q4 | -167.21 Thousand USD | 61.07% |
| 2008 Q2 | -615.32 Thousand USD | -81.63% |
| 2008 Q1 | -338.77 Thousand USD | 71.14% |
| 2007 Q1 | -286.36 Thousand USD | -308.16% |
| 2007 Q4 | -1.17 Million USD | -16.47% |
| 2007 Q3 | -1 Million USD | -287.3% |
| 2007 Q2 | -260.22 Thousand USD | 9.13% |
| 2007 FY | -2.72 Million USD | -38.66% |
| 2006 Q2 | -1.58 Million USD | -639.06% |
| 2006 Q1 | -215.04 Thousand USD | 82.13% |
| 2006 Q3 | -300.84 Thousand USD | 81.07% |
| 2006 Q4 | 137.57 Thousand USD | 145.73% |
| 2006 FY | -1.96 Million USD | 61.39% |
| 2005 Q3 | -66.52 Thousand USD | 98.12% |
| 2005 Q4 | -1.2 Million USD | -1708.49% |
| 2005 FY | -5.09 Million USD | 5.42% |
| 2005 Q2 | -3.53 Million USD | -1128.19% |
| 2005 Q1 | -288.1 Thousand USD | 91.56% |
| 2004 FY | -5.38 Million USD | -252.41% |
| 2004 Q3 | -229.01 Thousand USD | 66.69% |
| 2004 Q2 | -687.6 Thousand USD | 35.08% |
| 2004 Q1 | -1.05 Million USD | 15.97% |
| 2004 Q4 | -3.41 Million USD | -1390.11% |
| 2003 Q4 | -1.26 Million USD | -386.62% |
| 2003 Q3 | -259 Thousand USD | -7426.88% |
| 2003 FY | -1.52 Million USD | -10176.89% |
| 2003 Q2 | -3441.00 USD | 0.0% |
| 2002 FY | -14.87 Thousand USD | 11.97% |
| 2001 FY | -16.9 Thousand USD | -48191.43% |
| 2001 Q3 | - USD | 0.0% |
| 2000 FY | -35.00 USD | 0.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| Burzynski Research Institute, Inc. | -1.33 Million USD | 68.888% |
| Arch Therapeutics, Inc. | -6.98 Million USD | 94.05% |
| Evofem Biosciences, Inc. | 52.97 Million USD | 100.784% |
| Nascent Biotech, Inc. | -2.08 Million USD | 80.099% |
| Rebus Holdings, Inc. | -1.02 Million USD | 59.267% |
| Santhera Pharmaceuticals Holding AG | 65.13 Million USD | 100.638% |
| Qrons Inc. | -789.34 Thousand USD | 47.364% |
| Adynxx, Inc. | - USD | Infinity% |
| Neon Bloom, Inc. | -632.4 Thousand USD | 34.302% |
| Northwest Biotherapeutics, Inc. | -62.59 Million USD | 99.336% |
| Skye Bioscience, Inc. | -37.64 Million USD | 98.896% |
| Eiger BioPharmaceuticals, Inc. | -74.96 Million USD | 99.446% |
| Nanobac Pharmaceuticals, Incorporated | -6.57 Million USD | 93.682% |
| Institute of Biomedical Research Corp. | -273.4 Thousand USD | -51.966% |
| SQZ Biotechnologies Company | -79.46 Million USD | 99.477% |
| Intellipharmaceutics International Inc. | -2.89 Million USD | 85.635% |
| Propanc Biopharma, Inc. | -1.82 Million USD | 77.178% |
| Mesoblast Limited | -87.95 Million USD | 99.528% |
| Marizyme, Inc. | -65.34 Million USD | 99.364% |
| Genus plc | 7.9 Million USD | 105.259% |
| VioQuest Pharmaceuticals, Inc. | -10.89 Million USD | 96.185% |
| Pharming Group N.V. | -10.54 Million USD | 96.061% |
| Therapeutic Solutions International, Inc. | -2.16 Million USD | 80.852% |
| CNBX Pharmaceuticals Inc. | -3.71 Million USD | 88.802% |
| Nymox Pharmaceutical Corporation | -8.84 Million USD | 95.302% |
| ContraFect Corporation | -65.15 Million USD | 99.362% |
| PsyBio Therapeutics Corp. | -4.88 Million USD | 91.497% |
| Sienna Biopharmaceuticals, Inc. | - USD | Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | -1.72 Million USD | 75.948% |
| IMV Inc. | -36.48 Million USD | 98.861% |
| AXIM Biotechnologies, Inc. | -8.05 Million USD | 94.845% |
| MultiCell Technologies, Inc. | -380.07 USD | -109216.442% |
| ONE Bio Corp. | 8.67 Million USD | 104.788% |
| Accustem Sciences Inc. | -3.74 Million USD | 88.91% |
| RVL Pharmaceuticals plc | -51.69 Million USD | 99.196% |
| Arno Therapeutics, Inc. | - USD | Infinity% |
| EV Biologics, Inc. | -1.26 Million USD | 67.211% |
| Q BioMed Inc. | -2.05 Million USD | 79.753% |
| Emmaus Life Sciences, Inc. | -3.73 Million USD | 88.87% |
| Mosaic ImmunoEngineering Inc. | -2.38 Million USD | 82.549% |
| Biomind Labs Inc. | -1.21 Million USD | 65.785% |
| American Oriental Bioengineering, Inc. | -59.72 Million USD | 99.304% |
| Provectus Biopharmaceuticals, Inc. | -3.1 Million USD | 86.605% |
| TetraLogic Pharmaceuticals Corporation | - USD | Infinity% |
| Oncotelic Therapeutics, Inc. | -7.9 Million USD | 94.743% |
| GlobeStar Therapeutics Corporation | -1.94 Million USD | 78.685% |
| THC Farmaceuticals, Inc. | -14.97 Thousand USD | -2674.299% |
| Acro Biomedical Co., Ltd. | -15.87 Million USD | 97.382% |
| Curative Biotechnology, Inc. | -5.81 Million USD | 92.858% |
| GB Sciences, Inc. | -1.36 Million USD | 69.488% |
| Alpha Cognition Inc. | -13.77 Million USD | 96.983% |
| HST Global, Inc. | -146.21 Thousand USD | -184.166% |
| CSL Limited | 2.64 Billion USD | 100.016% |
| Wesana Health Holdings Inc. | -1.75 Million USD | 76.323% |
| Halberd Corporation | -79.67 Thousand USD | -421.461% |
| Enzolytics Inc. | -2.17 Million USD | 80.914% |
| Agentix Corp. | -1.37 Million USD | 69.766% |
| Resverlogix Corp. | -3.61 Million USD | 88.491% |
| Nuo Therapeutics, Inc. | -3.17 Million USD | 86.899% |
| MetaStat, Inc. | - USD | Infinity% |
| argenx SE | -295.05 Million USD | 99.859% |
| Enzon Pharmaceuticals, Inc. | 98 Thousand USD | 523.958% |
| Endonovo Therapeutics, Inc. | 6.92 Million USD | 106.0% |
| RespireRx Pharmaceuticals Inc. | -3.97 Million USD | 89.542% |
| GeneThera, Inc. | - USD | Infinity% |
| Inhibitor Therapeutics, Inc. | -3.02 Million USD | 86.27% |
| AVAX Technologies, Inc. | -6.41 Million USD | 93.522% |
| Zenith Capital Corp. | -10.59 Million USD | 96.079% |
| Genscript Biotech Corporation | -95.47 Million USD | 99.565% |
| Ember Therapeutics, Inc. | -23.24 Thousand USD | -1687.622% |
| Anthera Pharmaceuticals, Inc. | - USD | Infinity% |
| Sigyn Therapeutics, Inc. | -4.14 Million USD | 89.979% |
| WPD Pharmaceuticals Inc. | -60.44 Thousand USD | -587.417% |
| Cotinga Pharmaceuticals Inc. | -2 Million USD | 79.279% |
| Kadimastem Ltd | -3.3 Million USD | 87.438% |
| Helix BioMedix, Inc. | -1.05 Million USD | 60.658% |
| VitaSpring Biomedical Co. Ltd. | - USD | Infinity% |
| Capstone Therapeutics Corp. | -3.81 Million USD | 89.121% |
| BioStem Technologies, Inc. | -8.48 Million USD | 95.102% |
| Oncology Pharma Inc. | - USD | Infinity% |
| Reve Technologies, Inc. | -441.36 Thousand USD | 5.866% |
| LadRx Corporation | 400.44 Thousand USD | 203.755% |
| Cell Source, Inc. | -5.32 Million USD | 92.192% |
| Regen BioPharma, Inc. | 1.02 Million USD | 140.594% |
| Regen BioPharma, Inc. | 1.02 Million USD | 140.594% |
| NovAccess Global Inc. | -4.76 Million USD | 91.288% |
| Affymax, Inc. | -14.42 Million USD | 97.12% |
| Itoco Inc. | -1.86 Million USD | 77.77% |
| Rasna Therapeutics, Inc. | -4.44 Million USD | 90.648% |
| Pathfinder Cell Therapy, Inc. | -1.66 Million USD | 75.106% |
| Mobile Lads Corp. | -2.26 Million USD | 81.643% |
| CytoDyn Inc. | -49.84 Million USD | 99.166% |
| Claritas Pharmaceuticals, Inc. | - USD | Infinity% |
| NDT Pharmaceuticals Inc. | -79.03 Thousand USD | -425.703% |
| NanoSphere Health Sciences Inc. | -228.12 Thousand USD | -82.126% |
| Alseres Pharmaceuticals, Inc. | -941.52 Thousand USD | 55.872% |
| SYBLEU INC | -180.3 Thousand USD | -130.432% |
| Advanced Proteome Therapeutics Corporation | - USD | Infinity% |
| ImmunoCellular Therapeutics, Ltd. | -1.61 Million USD | 74.238% |
| International Stem Cell Corporation | -131 Thousand USD | -217.16% |
| Bioxytran, Inc. | -4.28 Million USD | 90.293% |
| GlobeImmune, Inc. | - USD | Infinity% |
| Predictive Technology Group, Inc. | - USD | Infinity% |
| ProText Mobility, Inc. | -54.27 Thousand USD | -665.549% |
| Cardax, Inc. | - USD | Infinity% |
| VG Life Sciences Inc. | -2.53 Million USD | 83.58% |
| Kaleido Biosciences, Inc. | - USD | Infinity% |
| Advaxis, Inc. | -48.07 Million USD | 99.136% |
| Adhera Therapeutics, Inc. | -2.11 Million USD | 80.346% |
| RenovaCare, Inc. | - USD | Infinity% |
| Regnum Corp. | -780.88 Thousand USD | 46.794% |
| Innovation Pharmaceuticals Inc. | -3.16 Million USD | 86.885% |
| Neutra Corp. | -233.46 Thousand USD | -77.962% |
| Windtree Therapeutics, Inc. | -20.29 Million USD | 97.952% |
| PureTech Health plc | -65.69 Million USD | 99.368% |
| Coeptis Therapeutics, Inc. | -21.26 Million USD | 98.046% |
| IXICO plc | -1.17 Million USD | 64.73% |
| IntelGenx Technologies Corp. | -9.92 Million USD | 95.815% |
| Gelesis Holdings, Inc. | -57.12 Million USD | 99.273% |
| CSL Limited | 2.64 Billion USD | 100.016% |
| Cellectis S.A. | -103.17 Million USD | 99.597% |